Ali-Jackson Kamil 4
4 · Aclaris Therapeutics, Inc. · Filed Jan 5, 2022
Insider Transaction Report
Form 4
Ali-Jackson Kamil
Chief Legal Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2022-01-03−27,905→ 0 total→ Common Stock (34,350 underlying) - Exercise/Conversion
Restricted Stock Unit
2022-01-03−6,638→ 0 total→ Common Stock (19,914 underlying) - Exercise/Conversion
Common Stock
2022-01-03+3,875→ 118,571 total - Exercise/Conversion
Common Stock
2022-01-03+27,905→ 146,476 total - Exercise/Conversion
Common Stock
2022-01-03+6,638→ 153,114 total - Exercise/Conversion
Common Stock
2022-01-03+7,100→ 160,214 total - Exercise/Conversion
Restricted Stock Units
2022-01-03−3,875→ 0 total→ Common Stock (3,875 underlying) - Exercise/Conversion
Restricted Stock Units
2022-01-03−7,100→ 0 total→ Common Stock (28,400 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- [F2]Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
- [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- [F4]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- [F5]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- [F6]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.